Cost-effectiveness of model-based eligibility for lung cancer screening in the routine clinical practice

Affiliations

¹ Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Medical Oncology, ASST Spedali Civili, Brescia, Italy.

Editorial

Salvatore Intagliata et al. Ann Transl Med. 2018 Sep.

. 2018 Sep;6(18):369.

doi: 10.21037/atm.2018.07.24.

¹ Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Medical Oncology, ASST Spedali Civili, Brescia, Italy.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Risk-Targeted Lung Cancer Screening: A Cost-Effectiveness Analysis.
Kumar V, Cohen JT, van Klaveren D, Soeteman DI, Wong JB, Neumann PJ, Kent DM. Kumar V, et al. Ann Intern Med. 2018 Feb 6;168(3):161-169. doi: 10.7326/M17-1401. Epub 2018 Jan 2. Ann Intern Med. 2018. PMID: 29297005 Free PMC article.

1. American Cancer Society. Cancer Facts & Figures 2018. Atlanta, Ga. 2018.
1. Jemal A, Center MM, DeSantis C, et al. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010;19:1893-907. 10.1158/1055-9965.EPI-10-0437 - DOI - PubMed
1. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409. 10.1056/NEJMoa1102873 - DOI - PMC - PubMed
1. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst 2010;102:605-13. 10.1093/jnci/djq099 - DOI - PubMed
1. Kumar V, Cohen JT, van Klaveren D, et al. Risk-Targeted Lung Cancer Screening: A Cost-Effectiveness Analysis. Ann Intern Med 2018;168:161-9. 10.7326/M17-1401 - DOI - PMC - PubMed